Search Results - Christian Heidbreder
- Showing 1 - 19 results of 19
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Selective dopamine D<sub>3</sub> receptor antagonism by SB‐277011A attenuates cocaine reinforcement as assessed by progressive‐ratio and variable‐cost–variable‐payoff fixed‐ratio c... by Zheng‐Xiong Xi, Jeremy G. Gilbert, Arlene C. Pak, Charles R. Ashby, Christian Heidbreder, Eliot L. Gardner
Published 2005Artigo -
9
The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions by Arlene C. Pak, Charles R. Ashby, Christian Heidbreder, Maria Pilla, Jeremy G. Gilbert, Zheng‐Xiong Xi, Eliot L. Gardner
Published 2006Artigo -
10
-
11
Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study by Walter Ling, Vijay R. Nadipelli, Caitlyn T. Solem, Naoko Ronquest, Yu‐Chen Yeh, Susan M. Learned, Vishaal Mehra, Christian Heidbreder
Published 2019Artigo -
12
-
13
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder by Azmi Nasser, Mark K. Greenwald, Bradley Vince, Paul J. Fudala, Philip Twumasi‐Ankrah, Yongzhen Liu, J. P. Jones, Christian Heidbreder
Published 2015Artigo -
14
The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation rewa... by Krista J. Spiller, Zheng‐Xiong Xi, Xiao‐Qing Peng, Amy Hauck Newman, Charles R. Ashby, Christian Heidbreder, J. Gaál, Eliot L. Gardner
Published 2007Artigo -
15
-
16
Acute administration of SB‐277011A, NGB 2904, or BP 897 inhibits cocaine cue‐induced reinstatement of drug‐seeking behavior in rats: Role of dopamine D<sub>3</sub> receptors by Jeremy G. Gilbert, Amy Hauck Newman, Eliot L. Gardner, Charles R. Ashby, Christian Heidbreder, Arlene C. Pak, Xiao‐Qing Peng, Zheng‐Xiong Xi
Published 2005Artigo -
17
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study by Walter Ling, Vijay R. Nadipelli, Arnie Aldridge, Naoko Ronquest, Caitlyn T. Solem, Howard D. Chilcoat, Victoria A. Albright, Courtney Johnson, Susan M. Learned, Vishaal Mehra, Christian Heidbreder
Published 2020Artigo -
18
Occupancy of Brain Dopamine D3 Receptors and Drug Craving: A Translational Approach by Manolo Mugnaini, Laura Iavarone, Palmina Cavallini, Cristiana Griffante, Beatrice Oliosi, Chiara Savoia, John D. Beaver, Eugenii A. Rabiner, Fabrizio Micheli, Christian Heidbreder, Anne C. Andorn, Emilio Merlo Pich, Massimo Bani
Published 2012Artigo -
19
The AVPR1A Gene and Substance Use Disorders: Association, Replication, and Functional Evidence by Brion S. Maher, Vladimir I. Vladimirov, Shawn J. Latendresse, Dawn L. Thiselton, Rebecca McNamee, Moonsu Kang, Tim B. Bigdeli, Xiangning Chen, Brien P. Riley, John M. Hettema, Howard D. Chilcoat, Christian Heidbreder, Pierandrea Muglia, E. Lenn Murrelle, Danielle M. Dick, Fazil Alıev, Arpana Agrawal, Howard J. Edenberg, John R. Kramer, John I. Nürnberger, Jay A. Tischfield, Bernie Devlin, Robert E. Ferrell, Galina P. Kirillova, Ralph E. Tarter, Kenneth S. Kendler, Michael M. Vanyukov
Published 2011Artigo
Search Tools:
Related Subjects
Medicine
Receptor
Internal medicine
Pharmacology
Dopamine
Psychology
Neuroscience
Addiction
Dopamine receptor D3
Antagonist
Opioid
Psychiatry
Buprenorphine
Chemistry
Dopamine receptor
Opioid use disorder
Self-administration
Anesthesia
Biology
Dopamine receptor D2
Drug
Nicotine
Nucleus accumbens
Abstinence
Agonist
Brain stimulation reward
Extinction (optical mineralogy)
Mineralogy
(+)-Naloxone
Antagonism